IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?
The possibility of extrapolation of indications for biosimilars is one of the issues widely discussed in modern literature. Currently, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have identified specific conditions under which for biosimilars extrapolation of indic...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2016-06-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/137 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568634572013568 |
|---|---|
| author | S. V. Orlov N. L. Shimanovskii S. N. Fogt |
| author_facet | S. V. Orlov N. L. Shimanovskii S. N. Fogt |
| author_sort | S. V. Orlov |
| collection | DOAJ |
| description | The possibility of extrapolation of indications for biosimilars is one of the issues widely discussed in modern literature. Currently, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have identified specific conditions under which for biosimilars extrapolation of indications is possible. In2015, athe first bioanalogue bevacizumab, (produced by JSC "BIOCAD"), has been registered. The article provides summary of the pivotal clinical study of Bevacizumab bioanalogue conducted in patients with non-small cell lung cancer. The article includes detailed scientific justification for the extrapolation of data on the efficacy, safety and immunogenicity obtained in the pivotal study to other indications, registered for the original bevacizumab drug. |
| format | Article |
| id | doaj-art-4c71844fa9994b60b1466bb1be0e7891 |
| institution | Kabale University |
| issn | 2410-1893 |
| language | Russian |
| publishDate | 2016-06-01 |
| publisher | QUASAR, LLC |
| record_format | Article |
| series | Исследования и практика в медицине |
| spelling | doaj-art-4c71844fa9994b60b1466bb1be0e78912025-02-03T00:57:39ZrusQUASAR, LLCИсследования и практика в медицине2410-18932016-06-0132455210.17709/2409-2231-2016-3-2-6103IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?S. V. Orlov0N. L. Shimanovskii1S. N. Fogt2First Saint Petersburg State Medical University named after Academician I.P. Pavlov, Saint PetersburgNational Research Medical University named after N.I. Pirogov, MoscowBIOCAD JSCSaint PetersburgThe possibility of extrapolation of indications for biosimilars is one of the issues widely discussed in modern literature. Currently, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have identified specific conditions under which for biosimilars extrapolation of indications is possible. In2015, athe first bioanalogue bevacizumab, (produced by JSC "BIOCAD"), has been registered. The article provides summary of the pivotal clinical study of Bevacizumab bioanalogue conducted in patients with non-small cell lung cancer. The article includes detailed scientific justification for the extrapolation of data on the efficacy, safety and immunogenicity obtained in the pivotal study to other indications, registered for the original bevacizumab drug.https://www.rpmj.ru/rpmj/article/view/137bevacizumabsafetybiosimilarbcd-021non-small cell lung carcinomaextrapolation of indicationsefficacy |
| spellingShingle | S. V. Orlov N. L. Shimanovskii S. N. Fogt IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG? Исследования и практика в медицине bevacizumab safety biosimilar bcd-021 non-small cell lung carcinoma extrapolation of indications efficacy |
| title | IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG? |
| title_full | IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG? |
| title_fullStr | IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG? |
| title_full_unstemmed | IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG? |
| title_short | IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG? |
| title_sort | is it possible to use bevacizumab biosimilar in all indications registered for original drug |
| topic | bevacizumab safety biosimilar bcd-021 non-small cell lung carcinoma extrapolation of indications efficacy |
| url | https://www.rpmj.ru/rpmj/article/view/137 |
| work_keys_str_mv | AT svorlov isitpossibletousebevacizumabbiosimilarinallindicationsregisteredfororiginaldrug AT nlshimanovskii isitpossibletousebevacizumabbiosimilarinallindicationsregisteredfororiginaldrug AT snfogt isitpossibletousebevacizumabbiosimilarinallindicationsregisteredfororiginaldrug |